Axcan to buy Eurand for $583 million
This article was originally published in Scrip
Executive Summary
Axcan is to acquire partner Eurand, a Dutch-based speciality pharma firm, for $583 million in cash, or $12 per share. The offer is a 9% premium over Eurand's close prior to the deal being announced and a 31% premium to its share price 90 days ago.